Valneva SE (VALN) Financial Ratios
20 years of historical data (2005–2024) · Healthcare · Biotechnology
EV/EBITDA
13.63
↑+26% vs avg
5yr avg: 10.79
30Y Low10.8·High10.8
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.79
↓-73% vs avg
5yr avg: 6.63
30Y Low1.7·High15.9
ROE
↑
-7.9%
↓+85% vs avg
5yr avg: -51.9%
30Y Low-73%·High3%
Debt/EBITDA
6.57
+0% vs avg
5yr avg: 6.57
30Y Low4.4·High35.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VALN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Valneva SE currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $470M | $307M | $719M | $734M | $2.7B | — | — | — | — | — | — |
| Enterprise Value | $526M | $355M | $802M | $597M | $2.5B | — | — | — | — | — | — |
| P/E Ratio → | -27.12 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.36 | 1.81 | 4.68 | 2.03 | 7.78 | — | — | — | — | — | — |
| P/B Ratio | 1.79 | 1.69 | 5.60 | 3.34 | 15.88 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 35.23 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VALN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Valneva SE's enterprise value stands at 13.6x EBITDA, 26% above its 5-year average of 10.8x. This is roughly in line with the Healthcare sector median of 14.1x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.09 | 5.21 | 1.65 | 7.12 | — | — | — | — | — | — |
| EV / EBITDA | 13.63 | 10.79 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 33.65 | 28.41 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
VALN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Valneva SE earns an operating margin of 7.9%. Operating margins have expanded from -31.4% to 7.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -7.9% indicates the company is currently destroying shareholder equity. ROIC of 4.5% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.9% | 41.9% | 34.4% | 10.2% | 46.0% | 50.8% | 60.4% | 61.6% | 56.3% | 54.2% | 40.1% |
| Operating Margin | 7.9% | 7.9% | -53.4% | -31.4% | -17.6% | -50.0% | -0.6% | 5.5% | -3.8% | -45.3% | -25.4% |
| Net Profit Margin | -7.2% | -7.2% | -66.0% | -39.7% | -21.1% | -58.4% | -1.4% | 2.9% | -10.9% | -52.3% | -26.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.9% | -7.9% | -58.3% | -73.4% | -59.2% | -60.6% | -1.3% | 2.8% | -11.9% | -40.3% | -15.3% |
| ROA | -2.6% | -2.6% | -18.8% | -19.9% | -11.6% | -18.0% | -0.7% | 1.6% | -5.8% | -20.4% | -8.2% |
| ROIC | 4.5% | 4.5% | -41.9% | -797.3% | — | -61.5% | -0.4% | 3.7% | -2.1% | -18.1% | -8.0% |
| ROCE | 3.9% | 3.9% | -25.4% | -28.6% | -17.0% | -22.2% | -0.4% | 3.7% | -2.5% | -21.5% | -9.3% |
VALN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Valneva SE carries a Debt/EBITDA ratio of 6.6x, which is highly leveraged (102% above the sector average of 3.3x). Net debt stands at $48M ($216M total debt minus $168M cash). Interest coverage of just 0.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.19 | 1.19 | 1.63 | 0.69 | 0.67 | 1.36 | 0.63 | 0.40 | 0.77 | 0.82 | 0.71 |
| Debt / EBITDA | 6.57 | 6.57 | — | — | — | — | 11.04 | 4.40 | 9.95 | — | — |
| Net Debt / Equity | — | 0.27 | 0.65 | -0.62 | -1.36 | -1.28 | 0.15 | -0.14 | 0.41 | 0.47 | 0.42 |
| Net Debt / EBITDA | 1.46 | 1.46 | — | — | — | — | 2.69 | -1.49 | 5.28 | — | — |
| Debt / FCF | — | — | — | — | — | -0.84 | — | -1.48 | 4.32 | 16.73 | — |
| Interest Coverage | 0.56 | 0.56 | -3.52 | -5.95 | -3.62 | -5.13 | -0.31 | 1.65 | -0.78 | -6.99 | -2.05 |
VALN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Valneva SE's current ratio of 2.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.14x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.53x to 2.61x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | 2.61 | 1.65 | 1.53 | 1.59 | 1.75 | 3.13 | 2.93 | 2.22 | 2.35 | 2.51 |
| Quick Ratio | 2.14 | 2.14 | 1.37 | 1.40 | 1.25 | 1.60 | 2.50 | 2.40 | 1.69 | 1.76 | 1.93 |
| Cash Ratio | 1.47 | 1.47 | 0.79 | 1.04 | 0.94 | 1.16 | 1.56 | 1.79 | 0.89 | 0.91 | 0.90 |
| Asset Turnover | — | 0.34 | 0.33 | 0.58 | 0.43 | 0.25 | 0.48 | 0.49 | 0.56 | 0.45 | 0.28 |
| Inventory Turnover | 1.84 | 1.84 | 2.27 | 9.24 | 1.51 | 2.02 | 1.94 | 1.91 | 2.31 | 1.90 | 1.76 |
| Days Sales Outstanding | — | 75.78 | 98.89 | 24.16 | 46.15 | 63.63 | 69.50 | 36.36 | 61.09 | 65.63 | 73.38 |
VALN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Valneva SE does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $70M | $69M | $58M | $49M | $45M | $46M | $41M | $39M | $37M | $36M |
Peer Comparison
Compare VALN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VALNYou | $470M | -27.1 | 13.6 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
 NVAX | $2B | 3.7 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 DYAI | $28M | -3.8 | — | — | 65.8% | -168.8% | -139.2% | -1669.3% | — |
 IBRX | $8B | -13.5 | — | — | 100.0% | -2334.2% | — | — | — |
 SIGA | $337M | 14.2 | -6387033.2 | 6.9 | 68.0% | 25.1% | 0.0% | 0.0% | 0.0 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 GSK | $102B | 6.7 | 8.4 | 12.8 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 SNY | $106B | 18.4 | 10.9 | 10.1 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 BNTX | $24B | -18.0 | — | 75.6 | 77.6% | -22.6% | -5.7% | -4.3% | — |
 MRNA | $19B | -6.7 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
See VALN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VALN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VALN vs NVAX
Side-by-side business, growth, and profitability comparison vs Novavax, Inc..
Start ComparisonVALN — Frequently Asked Questions
Quick answers to the most common questions about buying VALN stock.
What is Valneva SE's P/E ratio?
Valneva SE's current P/E ratio is -27.1x. This places it at the 50th percentile of its historical range.
What is Valneva SE's EV/EBITDA?
Valneva SE's current EV/EBITDA is 13.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.8x.
What is Valneva SE's ROE?
Valneva SE's return on equity (ROE) is -7.9%. The historical average is -26.8%.
Is VALN stock overvalued?
Based on historical data, Valneva SE is trading at a P/E of -27.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Valneva SE's profit margins?
Valneva SE has 41.9% gross margin and 7.9% operating margin.
How much debt does Valneva SE have?
Valneva SE's Debt/EBITDA ratio is 6.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.